Q3 2025 Absci Corp Earnings Call Transcript
Key Points
- Absci Corp (ABSI) reported favorable safety profiles with no serious adverse events in their ongoing ABS-101 Phase I trial.
- The company is accelerating the development of ABS-201 for androgenetic alopecia (AGA) and plans to initiate a Phase 1/2a trial in December 2025.
- ABS-201 is being developed for a second indication, endometriosis, with a Phase 2 trial expected to start in Q4 2026.
- The company has a strong cash position, with $152.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025, sufficient to fund operations into the first half of 2028.
- Absci Corp (ABSI) is expanding its AI platform capabilities, which has generated partnership interest and potential collaborations with large pharmaceutical companies.
- ABS-101 did not demonstrate an extended half-life compared to next-generation anti-TL1A competitor programs.
- The company decided to seek a partner for ABS-101 and will not pursue additional internal clinical development for this asset.
- Research and development expenses increased to $19.2 million for the quarter, driven by external preclinical and clinical development costs.
- The company faces significant competition in the IBD space, influencing their decision to reallocate resources to ABS-201.
- There is a need for careful trial design and patient recruitment strategies for the upcoming ABS-201 trials in both AGA and endometriosis.
Thank you for standing by. My name is Rochelle, and I will be your operator today. At this time, I would like to welcome everyone to the Absci Q3 2025 business update. (Operator Instructions)
Thank you. I will now turn the conference call over to Alex Khan, VP of Finance and Investor Relations. Please go ahead.
Thank you. Earlier today, Absci released the financial and operating results for the quarter ended September 30, 2025. If you haven't received this news release, or if you would like to be added to the company's distribution list, please send an email to [email protected].
An archived webcast of this call will be available for replay on Absci's Investor Relations website [email protected]. for at least 90 days after this call. Joining me today are Sean McClain, Absci's Founder and CEO; and Zach Jonasson, Chief Financial Officer and Chief Business Officer; Andreas Busch, Absci's Chief Innovation Officer, will also join for Q&A following
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
